Medicare Enrolled
Dr. Amit Shah, M.D.
Hematology · Sebring, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Shah from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shah? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Shah
Dr. Amit Shah is a hematology in Sebring, FL, with 20 years in practice. Based on federal Medicare data, Dr. Shah performed 186,701 Medicare services across 4,721 unique beneficiaries.
Between the years covered by Open Payments, Dr. Shah received a total of $27,165 from 101 pharmaceutical and/or device companies across 1349 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Shah is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 24% volume in FL$ $27,165 industry payments
Medicare Practice Summary
Medicare Utilization ↗186,701
Medicare services
Top 24% in FL for hematology
4,721
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9,335 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 77,010 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 22,400 | $42 | $137 |
| Filgrastim injection (Zarxio) for white blood cells | 17,400 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 16,920 | $18 | $51 |
| Anti-nausea injection (aprepitant) | 13,130 | $1 | $5 |
| Iron sucrose injection (Venofer) | 8,900 | $0 | $5 |
| Epoetin alfa injection (Procrit) for anemia | 6,730 | $6 | $23 |
| Daratumumab injection (Darzalex) | 6,660 | $38 | $110 |
| Immune globulin infusion (Gammagard) | 2,574 | $36 | $108 |
| Dexamethasone injection (steroid) | 2,216 | $0 | $3 |
| Complete blood count (CBC) with differential | 1,922 | $8 | $29 |
| Blood draw (venipuncture) | 1,847 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,300 | $1 | $28 |
| Drug injection, under skin or into muscle | 1,000 | $10 | $69 |
| Office visit, established patient (30-39 min) | 921 | $94 | $339 |
| Injection, leucovorin calcium, per 50 mg | 662 | $3 | $12 |
| Injection of additional new drug or substance into vein | 637 | $11 | $61 |
| Office visit, established patient (20-29 min) | 594 | $65 | $239 |
| Administration of chemotherapy into vein, 1 hour or less | 459 | $96 | $378 |
| Injection, fluorouracil, 500 mg | 407 | $2 | $7 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 322 | $1 | $6 |
| Anti-nausea injection (ondansetron/Zofran) | 296 | $0 | $9 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 222 | $46 | $189 |
| Hospital follow-up visit, moderate complexity | 173 | $62 | $197 |
| Administration of chemotherapy into vein, each additional hour | 164 | $21 | $79 |
| Injection of drug or substance into vein | 144 | $27 | $156 |
| Injection, zoledronic acid, 1 mg | 144 | $6 | $69 |
| Red blood count automated, with additional calculations | 130 | $5 | $20 |
| Injection, diphenhydramine hcl, up to 50 mg | 112 | $1 | $3 |
| New patient office visit (45-59 min) | 104 | $120 | $453 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 102 | $53 | $206 |
| Automated urinalysis | 93 | $2 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 93 | $15 | $56 |
| Infusion, normal saline solution , 1000 cc | 90 | $2 | $7 |
| Initial hospital admission, high complexity | 89 | $137 | $556 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 81 | $17 | $59 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 75 | $136 | $562 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 74 | $24 | $89 |
| Infusion into a vein for hydration, each additional hour | 69 | $10 | $42 |
| Administration of additional new drug or substance into vein using push technique | 68 | $41 | $170 |
| Administration of additional new drug or substance into vein, 1 hour or less | 65 | $48 | $178 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 64 | $22 | $84 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 58 | $3 | $11 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 51 | $127 | $637 |
| Infusion into a vein for hydration, 31-60 minutes | 48 | $24 | $156 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 37 | $15 | $56 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 30 | $1 | $7 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $60 | $192 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
43.0% high complexity
53.7% medium
3.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$27,165
Total received (2018-2024)
Avg $3,881/year across 7 years
Top 17% in FL for hematology
101
Companies
1,349
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$26,269 (96.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$897 (3.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$4,265
2023$5,492
2022$3,791
2021$3,621
2020$2,797
2019$3,554
2018$3,646
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$2,127
E.R. Squibb & Sons, L.L.C.
$1,735
Celgene Corporation
$1,720
Novartis Pharmaceuticals Corporation
$1,417
Janssen Biotech, Inc.
$1,377
PFIZER INC.
$1,284
Amgen Inc.
$1,225
Incyte Corporation
$1,003
Lilly USA, LLC
$990
Genentech USA, Inc.
$945
Seagen Inc.
$776
Merck Sharp & Dohme LLC
$708
Merck Sharp & Dohme Corporation
$622
Astellas Pharma US Inc
$560
GENZYME CORPORATION
$533
Eisai Inc.
$475
Gilead Sciences, Inc.
$398
Daiichi Sankyo Inc.
$388
Bayer HealthCare Pharmaceuticals Inc.
$350
Bayer Healthcare Pharmaceuticals Inc.
$347
Takeda Pharmaceuticals U.S.A., Inc.
$328
GlaxoSmithKline, LLC.
$306
SOBI, INC
$273
Alexion Pharmaceuticals, Inc.
$262
Rigel Pharmaceuticals, Inc.
$257
Clovis Oncology, Inc.
$257
Foundation Medicine, Inc.
$241
AbbVie, Inc.
$238
Pharmacyclics LLC, An AbbVie Company
$229
EISAI INC.
$226
TESARO, Inc.
$223
Alnylam Pharmaceuticals Inc.
$206
Ipsen Biopharmaceuticals, Inc
$205
BeiGene USA, Inc.
$195
Dova Pharmaceuticals
$186
ASD SPECIALTY HEALTHCARE, LLC
$174
ARRAY BIOPHARMA INC
$173
Karyopharm Therapeutics Inc.
$149
Seattle Genetics, Inc.
$149
Adaptive Biotechnologies Corporation
$140
EMD Serono, Inc.
$140
Myriad Genetic Laboratories, Inc.
$135
Boehringer Ingelheim Pharmaceuticals, Inc.
$134
Regeneron Healthcare Solutions, Inc.
$131
Stemline Therapeutics Inc.
$127
Radius Health, Inc.
$125
Agios Pharmaceuticals, Inc.
$124
SANOFI-AVENTIS U.S. LLC
$124
Jazz Pharmaceuticals Inc.
$119
Deciphera Pharmaceuticals Inc.
$119
Pharmacyclics LLC, an AbbVie Company
$117
Exelixis Inc.
$102
TerSera Therapeutics LLC
$101
Apellis Pharmaceuticals, Inc.
$100
AbbVie Inc.
$97
MorphoSys, US Inc.
$97
ABBVIE INC.
$86
PUMA BIOTECHNOLOGY, INC.
$86
Janssen Pharmaceuticals, Inc
$85
ADC Therapeutics America, Inc.
$83
Pharmacosmos Therapeutics Inc.
$83
Kyowa Kirin, Inc.
$79
ImmunoGen, Inc.
$72
PharmaEssentia USA Corporation
$68
Helsinn Therapeutics (U.S.), Inc.
$68
Myovant Sciences Inc.
$61
Verastem, Inc.
$58
Sobi, Inc
$54
AMAG Pharmaceuticals, Inc.
$53
Boston Scientific Corporation
$48
Sumitomo Pharma America, Inc.
$47
CTI BioPharma Corp.
$45
Aveo Pharmaceuticals, Inc.
$42
INSYS Therapeutics Inc
$41
JAZZ PHARMACEUTICALS INC.
$41
Taiho Oncology, Inc.
$41
Acrotech Biopharma Inc.
$40
Kite Pharma, Inc.
$39
Blueprint Medicines Corporation
$39
Mirati Therapeutics, Inc.
$38
Genentech, Inc.
$38
AVEO Pharmaceuticals, Inc.
$37
Inogen, Inc.
$35
G1 Therapeutics, Inc.
$33
Genmab U.S., Inc.
$30
Dendreon Pharmaceuticals LLC
$30
Epizyme, Inc.,
$28
Puma Biotechnology, Inc.
$28
GE HEALTHCARE
$25
Global Blood Therapeutics, Inc.
$24
SERVIER PHARMACEUTICALS LLC
$19
Tolmar, Inc.
$18
Heron Therapeutics, Inc.
$18
TAIHO ONCOLOGY, INC.
$17
Acceleron Pharma, Inc.
$17
TOLMAR Pharmaceuticals, Inc.
$16
Spectrum Pharmaceuticals Inc.
$16
Sun Pharmaceutical Industries Inc.
$15
Sirtex Medical Inc
$13
NOVARTIS PHARMACEUTICALS CORPORATION
$12
Sysmex Inostics Inc
$12
Top 3 companies account for 20.5% of total payments
Associated products mentioned in payments ›
ABECMA · ADAKVEO · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · AMVUTTRA · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BAVENCIO · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · EVENITY · Elahere · Empaveli · Enhertu · Epkinly · Erleada · FASENRA · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Folotyn · GAZYVA · GENERAL THERAPIES · GILOTRIF · GIVLAARI · Gazyva · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · INQOVI · INREBIC · Imbruvica · Inrebic · JADENU · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · MYRISK · Monoferric · NERLYNX · NINLARO · Neulasta · Nexavar · Nplate · Nubeqa · OJJAARA · ONPATTRO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Odomzo · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Phesgo · Pomalyst · Poteligeo · Prolia · QINLOCK · Quzyttir · REBLOZYL · RETEVMO · RYBREVANT · RYDAPT · Reblozyl · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · SYNDROS · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tavalisse · Tibsovo · Trodelvy · Tymlos · ULTOMIRIS · Ultomiris · VALCHLOR · VENCLEXTA · VERZENIO · VONJO · VONVENDI · VOTRIENT · VYXEOS · Vectibix · Venclexta · Vonjo · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xtandi · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · Zoladex · clonoSEQ · myChoice CDx · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $15 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
1
Per 100K population
1.0
County median income
$55,581
Nearest hospital
HCA FLORIDA HIGHLANDS HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Shah is a mixed practice specialist, with above-average Medicare volume (top 24% in FL), and high industry engagement (low-engagement, top 17%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Shah experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Shah performed 77,010 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Shah receive payments from pharmaceutical companies?
Yes. Dr. Shah received a total of $27,165 from 101 companies across 1,349 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shah's costs compare to other hematologys in Sebring?
Dr. Shah's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shah) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Sebring
Browse hematologys in Sebring ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology